Retatrutide vs Tirzepatide: Triple vs Dual Agonist

Tirzepatide, sold as Zepbound for weight management and Mounjaro for type 2 diabetes, works on two hormone receptors and has several years of real-world prescribing behind it. Retatrutide, still in Eli Lilly’s development pipeline, adds a third receptor target and posted some of the largest weight-loss numbers reported for an obesity drug in a randomized trial. The extra target is also why retatrutide needs more scrutiny, not less, before it reaches pharmacies.

Two receptors versus three

Both drugs are built on the same basic idea: activating gut-hormone receptors that regulate appetite, insulin secretion, and gastric emptying, rather than blocking a receptor or forcing weight loss through stimulants.

• Tirzepatide is a dual agonist — it activates both the GIP (glucose-dependent insulinotropic polypeptide) receptor and the GLP-1 receptor. This is the same GLP-1 mechanism semaglutide uses, plus an added GIP component that appears to improve insulin sensitivity and may enhance the appetite-suppressing effect of GLP-1 activation.
• Retatrutide is a triple agonist — it activates GIP and GLP-1 receptors, and adds glucagon receptor agonism on top.

The glucagon piece is the meaningful structural difference, and it changes the pharmacology in a way that isn’t just “more of the same.”

What adding glucagon is supposed to do

Glucagon is usually thought of as insulin’s opposite: it raises blood glucose by triggering the liver to release stored glucose. That sounds like a strange thing to add to a weight-loss drug built around GLP-1 and GIP, both of which push glucose down. But glucagon receptor agonism also increases energy expenditure, largely by stimulating fat oxidation and thermogenesis in the liver, and it may increase lipolysis (fat breakdown) in adipose tissue. In theory, that gives retatrutide a mechanism for burning more energy, not just eating less — something older GLP-1-only drugs don’t really offer.

The tradeoff is real. Glucagon’s glucose-raising effect works against the glucose-lowering effect of GIP and GLP-1, so the net metabolic result depends heavily on the relative potency Lilly engineered into the molecule at each receptor. This isn’t a new idea — dual glucagon/GLP-1 “co-agonists” and oxyntomodulin analogs have been explored for over a decade with mixed results, partly because of this glucose-versus-energy-expenditure balancing act. Retatrutide’s early data suggest the balance worked in the reported trial, with glycemic measures still improving overall, but that balance is exactly the kind of thing longer, larger trials are meant to stress-test.

Retatrutide’s Phase 2 results are among the largest weight-loss numbers reported for an obesity drug in a randomized trial — but they come from one mid-size study, not the multi-thousand-patient Phase 3 program regulators require before approval.

The Phase 2 numbers, with the caveats attached

In the Phase 2 trial reported by Jastreboff and colleagues in the New England Journal of Medicine, participants with obesity who received the highest tested dose of retatrutide (12 mg weekly) lost roughly 24% of body weight on average at 48 weeks, compared with about 2% in the placebo group. That is a large number by the standards of any obesity drug studied to date, including tirzepatide’s own pivotal SURMOUNT-1 trial, which reported roughly 20-21% average weight loss at the highest dose over 72 weeks.

It’s tempting to read those two numbers side by side and conclude retatrutide is simply more effective. That comparison isn’t valid on its own: the trials differ in size, duration, dosing schedule, and patient population, and cross-trial comparisons routinely overstate differences that shrink or disappear once a head-to-head trial is run. Retatrutide’s Phase 3 program, run under the name TRIUMPH, is still ongoing, and that is the data set that will actually determine how the drug compares with tirzepatide and semaglutide at scale.

Tirzepatide vs. retatrutide at a glance

	Tirzepatide	Retatrutide
Receptor targets	GIP + GLP-1 (dual)	GIP + GLP-1 + glucagon (triple)
Regulatory status	FDA-approved	Investigational, Phase 3 ongoing
Brand names	Zepbound (weight), Mounjaro (T2D)	None yet
Evidence base	Multiple completed Phase 3 trials (SURMOUNT, SURPASS)	One published Phase 2 trial; Phase 3 (TRIUMPH) not yet reported
Reported weight loss, highest dose	~20-21% at 72 weeks (SURMOUNT-1)	~24% at 48 weeks (Phase 2) — not directly comparable
Common side effects	Nausea, vomiting, diarrhea, constipation	Similar GI effects, plus a heart rate increase noted in Phase 2
Available by prescription	Yes	No

Why it isn’t on the market yet

Phase 2 trials are designed to test dose ranges and get an early efficacy signal in a few hundred people; they are not built to catch rarer safety issues or confirm durability over years. Retatrutide’s Phase 2 data included an increase in resting heart rate at higher doses, which is worth watching given glucagon’s role in cardiovascular physiology, and the glucose-raising and glucose-lowering effects of the drug’s three targets need to be shown to stay balanced across a much larger, longer, and more diverse patient population before regulators will consider it. That’s what the ongoing Phase 3 program is for, and until it reports, retatrutide’s real-world safety and effectiveness profile remains unknown.

It’s also worth being direct about something the excitement around retatrutide has created: the drug is not legally available by prescription anywhere. Products marketed online as “research-grade retatrutide” are not FDA-regulated pharmaceuticals, and their purity, dosing accuracy, and manufacturing quality are not verified by any independent authority.

The takeaway

Tirzepatide has an established, if not enormous, evidence base and years of prescribing experience behind it. Retatrutide’s early results are genuinely striking, but they rest on one Phase 2 trial, and the third receptor target it adds comes with a real, not just theoretical, tradeoff between energy expenditure and glucose control that larger trials still need to confirm. Whether retatrutide ultimately outperforms tirzepatide, and whether its benefits justify its risks, is a question for completed Phase 3 data and a clinician weighing an individual patient’s history — not for an early trial readout.

Sources

• Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023.
• Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022.
• FDA. FDA Approves New Medication for Chronic Weight Management (Zepbound).
• ClinicalTrials.gov. Retatrutide (TRIUMPH Phase 3 program) study listings.